McBride Jacqueline M, Sheinson Daniel, Jiang Jenny, Lewin-Koh Nicholas, Werner Barbara G, Chow Jennifer K L, Wu Xiaoning, Tavel Jorge A, Snydman David R
Genentech, Inc., South San Francisco, California.
Department of Medicine and the Division of Geographic Medicine and Infectious Disease, Tufts Medical Center, and Tufts University School of Medicine, Boston, Masschusetts.
Open Forum Infect Dis. 2019 Jan 14;6(2):ofz003. doi: 10.1093/ofid/ofz003. eCollection 2019 Feb.
The rate of cytomegalovirus (CMV) viral load increase and peak viral loads are associated with CMV disease in kidney and liver transplant recipients, but relationships to disease severity or mortality have not been shown.
Using stored serial serum specimens from renal (n = 59) and liver (n = 35) transplant recipients (D+R-; CMV-seropositive donors, CMV-seronegative recipients) from 2 prospective, randomized, controlled, interventional prophylaxis trials of CMV immune globulin (CMVIG), CMV viral load was measured using the COBAS quantitative polymerase chain reaction assay and the World Health Organization CMV standard. Patients with severe CMV-associated disease were classified according to trial definitions. Pairwise comparisons of mean viral load among deceased, surviving diseased, and nondiseased patients were analyzed by 2-way analysis of variance. To determine if viral load could predict mortality, receiver operating characteristic (ROC) curves were constructed using area under the curve (AUC) of the viral load and peak viral concentration (V).
Viral load (mean log [AUC], peak viral load [V]) for patients with severe CMV disease was significantly higher compared with nondiseased patients ( < .001). Similarly, higher viral burden was significantly associated with mortality ( < .001). Viral load AUC and V AUROCs for predicting mortality were 0.796 and 0.824, respectively, for renal patients, and 0.769 and 0.807, respectively, for liver patients.
Using specimens from studies preceding the antiviral prophylaxis era, CMV viral load was associated with severe CMV disease and death, supporting CMV viral load quantification as a proxy for CMV disease severity and disease-associated mortality end points in solid organ transplantation.
巨细胞病毒(CMV)病毒载量的增加速率和峰值病毒载量与肾移植和肝移植受者的CMV疾病相关,但与疾病严重程度或死亡率的关系尚未明确。
利用来自两项前瞻性、随机、对照、干预性预防试验(使用CMV免疫球蛋白(CMVIG))的肾移植(n = 59)和肝移植(n = 35)受者(D+R-;CMV血清学阳性供者,CMV血清学阴性受者)的储存系列血清标本,采用COBAS定量聚合酶链反应检测法和世界卫生组织CMV标准测定CMV病毒载量。根据试验定义对严重CMV相关疾病患者进行分类。通过双向方差分析对死亡患者、存活患病患者和未患病患者的平均病毒载量进行成对比较。为确定病毒载量是否可预测死亡率,使用病毒载量和峰值病毒浓度(V)的曲线下面积(AUC)构建受试者工作特征(ROC)曲线。
与未患病患者相比,严重CMV疾病患者的病毒载量(平均对数[AUC],峰值病毒载量[V])显著更高(<0.001)。同样,更高的病毒负荷与死亡率显著相关(<0.001)。肾移植患者预测死亡率的病毒载量AUC和V的ROC分别为0.796和0.824,肝移植患者分别为0.769和0.807。
利用抗病毒预防时代之前的研究标本,CMV病毒载量与严重CMV疾病和死亡相关,支持将CMV病毒载量定量作为实体器官移植中CMV疾病严重程度和疾病相关死亡率终点的替代指标。